Loading...
•
Feb 28, 2022
AngioDynamics Q3 2022 Earnings Report
AngioDynamics' Q3 2022 financial results were announced, showing a slight increase in net sales despite facing macroeconomic headwinds.
Key Takeaways
AngioDynamics reported a 3.9% increase in net sales for the third quarter of fiscal year 2022, reaching $74.0 million. Med Tech sales grew by 28.6%, while Med Device sales declined by 2.8%. The company experienced a net loss of $5.0 million, or $0.13 per share, but adjusted earnings per share were $0.03. Gross margin was 52.2%, impacted by supply chain disruptions, procedural challenges, and inflation. The company reaffirmed its fiscal year 2022 guidance.
Net sales increased by 3.9% to $74.0 million compared to the prior-year quarter.
Med Tech sales grew by 28.6%, while Med Device sales decreased by 2.8% year over year.
Gross margin was 52.2%, a decrease of 190 basis points year over year.
The company reaffirms fiscal year 2022 guidance.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Revenue by Segment
Med Tech Revenue
CapyFin.comMed Device Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company continues to expect: Fiscal year 2022 net sales to be in the range of $310 to $315 million; Gross margin to be in the range of 52.0% to 54.0%; and Adjusted earnings per share in the range of a loss of $0.02 to a gain of $0.02.
Revenue & Expenses
Visualization of income flow from segment revenue to net income